Truist Financial
ADMA icon

Truist Financial’s ADMA Biologics ADMA Stock Holding History

Truist Financial’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Buy
14,685
+3,518
+32% +$55.5K ﹤0.01% 2694
2025
Q4 		$204K Buy
+11,167
New +$188K ﹤0.01% 2597
2025
Q2 		– Sell
-11,330
Closed -$225K – 2593
2025
Q1 		$225K Buy
+11,330
New +$196K ﹤0.01% 2306

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Truist Financial's ADMA Position: Q1 2026 in Review

Truist Financial increased its ADMA Biologics (ADMA) stake by 32% in Q1 2026, buying an estimated $55.5K and bringing the position to 14,685 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

Truist Financial first reported a position in ADMA in Q1 2025 and has held it in 3 quarters since. The position peaked at $225K in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Truist Financial held 14,685 shares of ADMA Biologics worth $132K as of Q1 2026.
  • Truist Financial bought 3,518 ADMA Biologics shares in Q1 2026, an estimated $55.5K.
  • ADMA Biologics made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2694 holding.
  • Truist Financial first reported a position in ADMA Biologics in Q1 2025 and has held it in 3 quarters since.
  • Truist Financial's ADMA Biologics position peaked at $225K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.